Literature DB >> 8902057

The MEN II syndromes and the role of the ret proto-oncogene.

B A Ponder1, D Smith.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8902057     DOI： 10.1016/s0065-230x(08)60875-1

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN： 0065-230X            Impact factor:   6.242


× No keyword cloud information.
  12 in total

1.  Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas.

Authors:  H Dannenberg; E J Speel; J Zhao; P Saremaslani; E van Der Harst; J Roth; P U Heitz; H J Bonjer; W N Dinjens; W J Mooi; P Komminoth; R R de Krijger
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.

Authors:  Syed A Ahmed; Karen Snow-Bailey; W Edward Highsmith; Weimin Sun; Raymond G Fenwick; Rong Mao
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

3.  Multiple intracranial recurrent tumors with hyperprolactinemia combined with a parasellar malignant fibrous histiocytoma long after transfrontal surgery and irradiation to a pituitary adenoma.

Authors:  M Fujikawa; K Okamura; K Sato; M Shiratsuchi; T Yao; T Mizokami; M Fujishima
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

4.  Novel mechanisms of early upper and lower urinary tract patterning regulated by RetY1015 docking tyrosine in mice.

Authors:  Masato Hoshi; Ekatherina Batourina; Cathy Mendelsohn; Sanjay Jain
Journal:  Development       Date:  2012-05-23       Impact factor: 6.868

5.  Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display.

Authors:  Thomas J Musholt; Julia Hanack; Christoph Brehm; Reinhard von Wasielewski; Petra B Musholt
Journal:  World J Surg       Date:  2005-04       Impact factor: 3.352

6.  C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B.

Authors:  C L Smith-Hicks; K C Sizer; J F Powers; A S Tischler; F Costantini
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

7.  Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity.

Authors:  D S Franklin; V L Godfrey; D A O'Brien; C Deng; Y Xiong
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

Review 8.  Gene therapeutic approaches for medullary thyroid carcinoma treatment.

Authors:  Matthias Drosten; Brigitte M Pützer
Journal:  J Mol Med (Berl)       Date:  2003-06-14       Impact factor: 4.599

9.  Organotypic specificity of key RET adaptor-docking sites in the pathogenesis of neurocristopathies and renal malformations in mice.

Authors:  Sanjay Jain; Amanda Knoten; Masato Hoshi; Hongtao Wang; Bhupinder Vohra; Robert O Heuckeroth; Jeffrey Milbrandt
Journal:  J Clin Invest       Date:  2010-02-15       Impact factor: 14.808

10.  Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform.

Authors:  Adrianne Wong; Silvia Bogni; Pille Kotka; Esther de Graaff; Vivette D'Agati; Frank Costantini; Vassilis Pachnis
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.